Kaposi’s sarcoma-associated herpesvirus (KSHV) is the causative agent of Kaposi’s sarcoma (KS), which is endangering human health worldwide, especially in Africa, Europe, the United States, and parts of Asia. The aim of this study was to investigate the prevalence of KSHV in Xinjiang. Three KSHV recombinant proteins (ORF65, ORF73, and K8.1) were used to detect KSHV infection. The serum samples to be tested were detected by an indirect ELISA method. The overall infection rate of KSHV in Xinjiang was 25.60%, with a higher infection rate in the Uygur population of 29.79%. After adjusting for possible confounders, Uygur (OR = 3.95, 95% CI 2.64–6.12, ), agriculture and livestock (OR = 1.60, 95% CI 1.20–2.17, = 0.002), age ≤ 50 years (OR = 1.50, 95% CI 1.13–2.00, = 0.006), and predominantly meat-based diet (OR = 1.72, 95% CI 1.11–2.78, = 0.018) were significantly associated with the odds of KSHV seropositivity correlation. Three unique sequences of KSHV were obtained in this study; genotypic analysis showed that the three unique sequences were all subtype A2.
Objective To investigate the effects of sodium fructose diphosphate (FDP) on blood coagulation reaction time and plasma coagulation factor activity in vitro. Method The thromboelastogram detection system provided by three different manufacturers (Maiketian, Lepu, and Dingrun) was used to determine the blood coagulation reaction time (R) , clotting time (K), α-angle, and maximal amplitude (MA) of blood samples mixed with different concentrations FDP and the samples before dosing.The activities of coagulation factors II, V, VII, VIII, IX, X, XI and XII for plasma mixed with FDP were determined by automatic hemagglutination analysis system. The difference of test results between the experimental group with FDP and the control group without FDP was compared. The correlation between FDP concentration and the results of thrombologram or coagulation factor activity was analyzed by linear regression. New Zealand white rabbits were selected for the experiment on the effect of the drug on blood coagulation in vivo, and the changes of the thrombologram test results (R, K, α-angle, MA) at each time point after injection of FDP groups with the same dose were analyzed. According to the changes of the thrombologram test results before and after injection, statistical analysis was conducted to determine whether there were statistical differences in the effect of the drug on blood coagulation function. Result The results of thrombologram provided by three different manufacturers showed that the R value of blood sample was significantly correlated with the blood FDP concentration (P < 0.000), and the correlation coefficient r was 0.988 (Maiketian), 0.999 (Lepu) and 0.996 (Dingrun), respectively. There was no significant correlation between FDP concentration and K, α-angle , or MA (P > 0.05). The results of in vitro experiments showed that plasma coagulation factor V, VII, IX, XI and XII activities were significantly negatively correlated with plasma FDP concentrations (P < 0.000), and the correlation coefficients r were -0.995, -0.990, -0.989, 0.997, 0.995, respectively. The activities of II, VIII and X were not significantly affected by FDP (P > 0.05). In vivo experiments of New Zealand white rabbits showed that 0.5h after intravenous 0.5g/Kg FDP administration , 0.5h, 1h and 1.5h after 1g/Kg administration, 0.5h, 1h and 1.5h after 2g/Kg administration, and 0.5h, 1h, 1.5h and 2h after 4g/Kg administration, there were statistical differences in the R values of thrombologram compared with those before administration (P < 0.05), and the R values increased significantly after administration. That is, the blood coagulation reaction time is prolonged. Conclusion FDP can affect the results of blood coagulation test in vivo and vitro. It may really affect the function of our coagulation system.
While fructose-1,6-diphosphate (FDP) has been clinically applied in ischemic conditions, its comprehensive effects on hemostasis remain to be fully elucidated. This in vitro study examined the influence of FDP on coagulation and platelet function using thromboelastography (TEG) across three platforms, coagulation factor assays, and platelet aggregation tests over a concentration range of 0–6 mg/mL. The results revealed that FDP concentration-dependently prolonged TEG R-time ( P < 0.01), with an increase of 21.8–48.3% at the clinically relevant concentration of 3.71 mg/mL. Strong inverse correlations were observed between FDP concentration and the activities of factors V, VII, IX, XI, and XII ( r = − 0.989 to − 0.997, P < 0.001), whereas factors II, VIII, and X remained unaltered. Furthermore, FDP significantly inhibited platelet aggregation ( P < 0.001), nearly abolishing epinephrine- and ADP-induced aggregation at 6 mg/mL under unbuffered conditions. pH-control experiments confirmed that the anticoagulant effects were FDP-specific, while the antiplatelet effects were primarily mediated by FDP with a partial pH-dependent component. These findings demonstrate that FDP possesses dual anticoagulant and antiplatelet properties through selective inhibition of coagulation initiation factors and broad suppression of platelet responsiveness, suggesting potential implications for clinical use in high-risk populations and warranting further investigation.
Objective: To investigate the effects of sodium fructose diphosphate (FDP) on blood coagulation parameters, including reaction time and plasma coagulation factor activity, in both in vitro and in vivo models. Methods: Three thromboelastography systems (Maiketian, Lepu, Dingrun) were used to assess coagulation parameters (reaction time [R], clotting time [K], α-angle, maximal amplitude [MA]) in blood samples spiked with varying FDP concentrations. An automatic coagulation analyzer quantified the activities of coagulation factors II, V, VII, VIII, IX, X, XI, and XII in FDP-treated plasma.Differences between FDP-treated and control groups were statistically compared. Linear regression analyzed correlations between FDP concentrations and coagulation parameters. For in vivo studies, New Zealand white rabbits received intravenous FDP (0.5, 1, 2, or 4 g/kg), and thromboelastography parameters were monitored at multiple time points post-administration (0.5-2 hours). Results: Thromboelastography demonstrated a strong positive correlation between FDP concentration and R values across all systems ( P < 0.001; r = 0.988 [Maiketian], 0.999 [Lepu], 0.996 [Dingrun]). No significant associations were observed between FDP and K, α-angle, or MA ( P > 0.05). In vitro experiments revealed significant negative correlations between FDP concentration and activities of factors V ( r = -0.995), VII ( r = -0.990), IX ( r = -0.989), XI ( r = -0.997), and XII ( r = -0.995) ( P < 0.001), while factors II, VIII, and X remained unaffected ( P > 0.05). In vivo administration demonstrated dose-dependent prolongation of R-time, reaching statistical significance (p < 0.05) at:0.5 g/kg: 0.5 hr post-dose,1 g/kg: 0.5-1.5 hr,2 g/kg: 0.5-1.5 hr,4 g/kg: 0.5-2 hr. Conclusion: FDP significantly impacts coagulation testing outcomes both in vitro and in vivo, potentially through modulation of intrinsic pathway factors (V, VII, IX, XI, XII) and direct interference with clot initiation. These findings suggest clinically relevant anticoagulant properties that warrant further investigation.